Loading...
•
Sep 30, 2024
Ocugen Q3 2024 Earnings Report
Ocugen reported financial results for the third quarter of 2024 and provided a business update.
Key Takeaways
Ocugen reported progress in its gene therapy programs, including the expansion of the OCU400 Phase 3 clinical trial into Canada. With recent financing, the company's cash runway extends into 1Q2026.
Closed $30 million in debt financing subsequent to quarter-end.
OCU400 Phase 3 liMeliGhT clinical trial for retinitis pigmentosa (RP) is on track to complete enrollment in 1H2025.
OCU410 is currently in Phase 2 of the Phase 1/2 ArMaDa clinical trial.
DSMB for the OCU410ST GARDian clinical trial approved enrollment for the second phase of the Phase 1/2 clinical trial.
Ocugen
Ocugen
Forward Guidance
Ocugen's cash runway extends into 1Q2026.